Search the Newsreel

Johnson & Johnson (JNJ) brings a 13.0% four-week climb into July 15 earnings

The Healthcare heavyweight has momentum in weekly context, while lighter volume keeps the pre-results setup from looking fully confirmed.

Johnson & Johnson’s 54.9M-share high tests the limit of an unconfirmed advance

JNJ jumped 11.5% to finish just 0.2% below its 52-week high, but negative activity pressure and a 52% Fair Value premium keep the weekly setup from being one-sided.

Johnson & Johnson (JNJ) insider filing adds an executive acquisition

The update gives investors a fresh ownership datapoint as the drugmaker is viewed through weekly market data rather than live intraday action.

Johnson & Johnson wins FDA approval for expanded Caplyta label

Wolfe Research reiterates Johnson & Johnson stock rating on FDA approval

Johnson & Johnson Remains A Safe Harbor For Investors - Grand Pinnacle Tribune

Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings